A pioneering trial for a potential rheumatoid arthritis treatment, focusing on the gut microbiome, is underway on the Sunshine Coast. The University of the Sunshine Coast Clinical Trials, in collaboration with Servatus Biopharmaceuticals Ltd, is seeking participants for the study of a Live Biotherapeutic Product, an emerging field in global medical therapy.
Rheumatoid arthritis, an autoimmune disease causing the immune system to mistakenly attack the body’s tissues, leading to joint pain and stiffness, affects daily living for many.
Principal Investigator Dr Peter de Wet expressed interest in understanding the role of the gut microbiome in alleviating symptoms, stating the need for new medicines due to the limitations of current treatments.
The trial, hosted at UniSC’s new Birtinya clinic, marks a significant advancement in the quest for innovative treatments. Dr Samantha Coulson, Head of Clinical Research at Servatus, highlighted the exciting potential of Live Biotherapeutic Products in treating autoimmune and inflammatory conditions.
The trial seeks participants aged 18 to 80 with confirmed rheumatoid arthritis, committing to up to six visits over four months at the Birtinya clinic. Participants will be reimbursed for their time.
Those interested in volunteering can find more information at
www.usc.edu.au/trials.
